Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

211
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
211
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

379
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
379
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

219
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
219
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

113
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
113
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

396
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Enhanced Separation Techniques for Oligonucleotides Utilizing Mixed-Mode Chromatography and 2D-LC/UV/MS Analysis.

Journal of separation science·2025
Same author

Identification of TRIM21 and TRIM14 as Antiviral Factors Against Langat and Zika Viruses.

Viruses·2025
Same author

Activation and signaling characteristics of the hydroxy-carboxylic acid 3 receptor identified in human neutrophils through a microfluidic flow cell technique.

Biochimica et biophysica acta. Molecular cell research·2025
Same author

Proteome characterization of extracellular vesicles from human milk: Uncovering the surfaceome by a lipid-based protein immobilization technology.

Journal of extracellular biology·2024
Same author

Psychiatric disorders and comorbidity in women with Turner Syndrome: a retrospective national cohort study.

Translational psychiatry·2024
Same author

Early clinical drug product shelf-life setting using accelerated predictive stability and metabolite data for impurity qualification: A case study.

Journal of pharmaceutical sciences·2024

Related Experiment Video

Updated: Mar 13, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.7K

Core-shell column Tanaka characterization and additional tests using active pharmaceutical ingredients.

Jufang Wu Ludvigsson1, Anders Karlsson1, Viktor Kjellberg1

  • 1Pharmaceutical Technology and Development, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Journal of Separation Science
|October 15, 2016
PubMed
Summary

Core-shell particles offer comparable performance to sub-2 µm fully porous particles in fast liquid chromatography, with significantly lower back pressure. This study characterized various core-shell C18 columns to assess their suitability for pharmaceutical analysis.

Keywords:
Batch-to-batch reproducibilityColumn efficiencyCore-shell particlesPeak shapeTanaka test

More Related Videos

Preparation of Nanoparticles for ToF-SIMS and XPS Analysis
06:24

Preparation of Nanoparticles for ToF-SIMS and XPS Analysis

Published on: September 13, 2020

9.2K
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.6K

Related Experiment Videos

Last Updated: Mar 13, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.7K
Preparation of Nanoparticles for ToF-SIMS and XPS Analysis
06:24

Preparation of Nanoparticles for ToF-SIMS and XPS Analysis

Published on: September 13, 2020

9.2K
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.6K

Area of Science:

  • Analytical Chemistry
  • Chromatography Science

Background:

  • Core-shell particles are increasingly utilized in fast liquid chromatography (FLC) due to their performance advantages.
  • They consist of a solid core with an outer porous shell, offering reduced back pressure compared to fully porous particles.
  • Their application in pharmaceutical analysis is growing, necessitating thorough characterization.

Purpose of the Study:

  • To characterize 17 commercially available core-shell C18 columns from various vendors.
  • To evaluate the batch-to-batch reproducibility of core-shell columns using active pharmaceutical ingredients (APIs).
  • To compare the efficiency of core-shell particles with sub-2 µm fully porous materials.

Main Methods:

  • Characterization of 17 core-shell C18 columns (dimensions: 50 mm × 2.1 mm to 100 mm × 3 mm; particle sizes: 1.6–2.7 µm) using Tanaka test protocols.
  • Investigation of batch-to-batch reproducibility using four selected APIs under isocratic elution.
  • Performance comparison with a fully porous BEH C18 (1.7 µm) column.

Main Results:

  • Core-shell columns demonstrated comparable performance to sub-2 µm fully porous particles.
  • Batch-to-batch reproducibility was investigated for different core-shell column types under isocratic and gradient elution.
  • The efficiency of 2.6–2.7 µm core-shell particles was confirmed to be comparable to sub-2 µm fully porous materials.

Conclusions:

  • Core-shell C18 columns are a viable option for fast liquid chromatography in pharmaceutical analysis.
  • Their performance and reproducibility support their adoption in the market.
  • These particles offer a balance of high efficiency and low back pressure.